Literature DB >> 8137133

Scrapie associated PrP accumulation and its prevention: insights from cell culture.

B Caughey1.   

Abstract

Transmissible spongiform encephalopathies (TSEs), Alzheimer's disease and other amyloidoses result in the accumulation of abnormally stable, potentially amyloidogenic proteins that appear to play central roles in disease pathogenesis. Scrapie-infected tissue culture cells have become well-developed models for studying how the TSE-specific protein, protease-resistant PrP, is made from its apparently normal precursor. The conversion of PrP to the protease-resistant state occurs on the plasma membrane or along an endocytic pathway to the lysosomes. The protease-resistant PrP has a much longer half-life than normal PrP and its accumulation in lysosomes may feature in TSE pathogenesis. Congo red and certain sulfated glycans potently inhibit protease-resistant PrP formation or stabilization in cell culture. These and other observations suggest that an interaction of PrP with glycosaminoglycans is critical in protease-resistant PrP accumulation and raises the possibility that therapeutic strategies for TSEs and other amyloidoses could be based on blocking (pre)amyloid-glycosaminoglycan interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8137133     DOI: 10.1093/oxfordjournals.bmb.a072651

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  13 in total

1.  Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.

Authors:  C Wong; L W Xiong; M Horiuchi; L Raymond; K Wehrly; B Chesebro; B Caughey
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

2.  Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update.

Authors:  B Caughey; G J Raymond; S A Priola; D A Kocisko; R E Race; R A Bessen; P T Lansbury; B Chesebro
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

Review 3.  Prion-like propagation of cytosolic protein aggregates: insights from cell culture models.

Authors:  Carmen Krammer; Hermann M Schätzl; Ina Vorberg
Journal:  Prion       Date:  2009-10-04       Impact factor: 3.931

4.  Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells.

Authors:  S A Priola; B Caughey; R E Race; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment.

Authors:  M Pérez; F Wandosell; C Colaço; J Avila
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

6.  Phosphorylation of prion protein at serine 43 induces prion protein conformational change.

Authors:  Paresa N Giannopoulos; Catherine Robertson; Julie Jodoin; Hemant Paudel; Stephanie A Booth; Andrea C LeBlanc
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

7.  Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected].

Authors:  B Caughey; K Brown; G J Raymond; G E Katzenstein; W Thresher
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

8.  Cell-surface prion protein interacts with glycosaminoglycans.

Authors:  Tao Pan; Boon-Seng Wong; Tong Liu; Ruliang Li; Robert B Petersen; Man-Sun Sy
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

9.  Prion disease induced alterations in gene expression in spleen and brain prior to clinical symptoms.

Authors:  Hyeon O Kim; Greg P Snyder; Tyler M Blazey; Richard E Race; Bruce Chesebro; Pamela J Skinner
Journal:  Adv Appl Bioinform Chem       Date:  2008-09-07

10.  Recombinant human prion protein inhibits prion propagation in vitro.

Authors:  Jue Yuan; Yi-An Zhan; Romany Abskharon; Xiangzhu Xiao; Manuel Camacho Martinez; Xiaochen Zhou; Geoff Kneale; Jacqueline Mikol; Sylvain Lehmann; Witold K Surewicz; Joaquín Castilla; Jan Steyaert; Shulin Zhang; Qingzhong Kong; Robert B Petersen; Alexandre Wohlkonig; Wen-Quan Zou
Journal:  Sci Rep       Date:  2013-10-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.